for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Precigen Inc

PGEN.OQ

Latest Trade

4.46USD

Change

0.25(+5.94%)

Volume

200,877

Today's Range

4.21

 - 

4.51

52 Week Range

1.26

 - 

7.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.21
Open
4.25
Volume
200,877
3M AVG Volume
41.81
Today's High
4.51
Today's Low
4.21
52 Week High
7.79
52 Week Low
1.26
Shares Out (MIL)
171.01
Market Cap (MIL)
719.97
Forward P/E
-7.02
Dividend (Yield %)
--

Next Event

Q2 2020 Precigen Inc Earnings Release

Latest Developments

More

Precigen Files For Mixed Shelf Of Upto $500 Mln

Precigen Reports First Quarter 2020 Financial Results

Intrexon Says Effective Immediately, Appointed Helen Sabzevari, As President And CEO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Precigen Inc

Precigen, Inc., formerly Intrexon Corporation, forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Industry

Biotechnology & Drugs

Contact Info

20374 SENECA MEADOWS PARKWAY

GERMANTOWN, MD

20876

United States

+1.301.5569900

https://www.dna.com/

Executive Leadership

Randal Joe Kirk

Executive Chairman of the Board

Helen Sabzevari

President, Chief Executive Officer, President - Precigen, Inc.

Rick L. Sterling

Chief Financial Officer

Jeffrey T. Perez

Senior Vice President - Intellectual Property Affairs

Donald P. Lehr

Chief Legal Officer

Key Stats

2.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.2K

2019

0.1K

2020(E)

0.1K
EPS (USD)

2017

-0.980

2018

-3.930

2019

-1.890

2020(E)

-0.600
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.41
Price To Book (MRQ)
8.24
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
254.30
LT Debt To Equity (MRQ)
216.36
Return on Investment (TTM)
-36.47
Return on Equity (TTM)
-31.50

Latest News

Latest News

BRIEF-Precigen Files For Mixed Shelf Of Upto $500 Mln

* PRECIGEN FILES FOR MIXED SHELF OF UPTO $500 MILLION - SEC FILING Source: https://bit.ly/2CnOXgT Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up